Pharmacogenetics in Heart Failure Trials

Heart Failure Clinics

Volumn 7, Issue 4, 2011, Pages 553-559

  Fiuzat, Mona ^a   Bristow, Michael R ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Adrenergic receptors; Clinical trials; Heart failure; Pharmacogenetics

Indexed keywords

ALDOSTERONE SYNTHASE; ANGIOTENSIN 1 RECEPTOR; ARGININE; BUCINDOLOL; CANDESARTAN; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUTAMINE; GLYCINE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; METOPROLOL; METOPROLOL SUCCINATE; SERINE;

ALLELE; BIVENTRICULAR ASSIST DEVICE; DEFIBRILLATION; DISEASE COURSE; DNA POLYMORPHISM; DRUG EFFICACY; DRUG SAFETY; EVENT FREE SURVIVAL; EXERCISE; FOLLOW UP; GENE DELETION; GENE INSERTION; GENETIC VARIABILITY; GENOTYPE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION COST; HUMAN; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PHARMACOGENETICS; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE;

CARDIOVASCULAR AGENTS; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; PHARMACOGENETICS;

EID: 80052944898     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2011.06.010     Document Type: Review

References (57)

1. Hudis C. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 2007, 357(1):39-51.
2. Hayes D.F., Thor A.D., Dressler L.G., et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007, 357(15):1496-1506.
3. Krause D.S., Van Etten R.A. Tyrosine kinase as targets for cancer therapy. N Engl J Med 2005, 353(2):172-187.
4. Innocenti F., Undevia S.D., Lyer L., et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004, 22:1382-1388.
5. Cote J.F., Kirzin S., Kramar A., et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 2007, 13:3269-3275.
6. Mallal S., Phillips E., Carosi G., et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008, 358:568-579.
7. Link E., Parish S., Armitage J., et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008, 359(8):789-799. SEARCH Collaborative Group.
8. Herman D., Locatelli I., Grabnar I., et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J 2005, 5(3):193-202.
9. Schwarz U.I., Ritchie M.D., Bradford Y., et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008, 358:999-1008.
10. Sotoodehnia N., Siscorick D.S., Vatta M., et al. β-2 Adrenergic receptor genetic variants and risk of sudden cardiac death. Circulation 2006, 113(15):1818-1820.
11. Rampersaud E., Damcott C.M., Fu M., et al. Identification of novel candidate genes for type 2 diabetes from a genome-wide association scan in the Old Order Amish: evidence for replication from diabetes-related quantitative traits and from independent populations. Diabetes 2007, 56:3053-3062.
12. Saxena R., Voight B.F., Lyssenko V., et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007, 316:1331-1336.
13. Sladek R., Rocheleau G., Rung J., et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007, 445:881-885.
14. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007, 447:661-678. Wellcome Trust Case Control Consortium.
15. Kathiresan S., Manning A.K., Demissie S., et al. A genome-wide association study for blood lipid phenotypes in the Framingham Heart Study. BMC Med Genet 2007, 8(Suppl 1):S17.
16. Shearman A.M., Ordovas J.M., Cupples L.A., et al. Evidence for a gene influencing the TG/HDL-C ratio on chromosome 7q32,3-qter: a genome-wide scan in the Framingham Study. Hum Mol Genet 2000, 9:1315-1320.
17. Peacock J.M., Arnett D.K., Atwood L.D., et al. Genome scan for quantitative trait loci linked to high-density lipoprotein cholesterol. The NHLBI Family Heart Study. Arterioscler Thromb Vasc Biol 2001, 21:1823-1828. On behalf of the Investigators of the NHLBI Family Heart Study.
18. O'Donnell C.J., Cupples L.A., D'Agostino R.B., et al. Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI's Framingham Heart Study. BMC Med Genet 2007, 8(Suppl 1):S4.
19. Samani N.J., Erdmann J., Hall A.S., et al. Genomewide association analysis of coronary artery disease. N Engl J Med 2007, 357(5):443-453.
20. Lloyd-Jones D., Adams R., Carnethon M., et al. Heart disease and stroke statistics update. Circulation 2009, 119:e21-e181.
21. Ezekowitz J.A., Kaul P., Bakal J.A., et al. Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. J Am Coll Cardiol 2009, 53:13-20.
22. Liggett S.B., Mialet-Perez J., Thaneemit-Chen S., et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A 2006, 103:11288-11293.
23. de Groote P., Helbecque N., Lamblin N., et al. Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenet Genomics 2005, 15:137-142.
24. Terra S.G., Hamilton K.K., Pauly D.F., et al. Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to β-blocker therapy. Pharmacogenet Genomics 2005, 15:227-234.
25. Rochais F., Vilardaga J.P., Nikolaev V., et al. Real-time optical recording of β1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. J Clin Invest 2007, 117(1):229-235.
26. Lindenfeld J.L., Plehn J.F., Liggett S.B., et al. Different patterns of LVEF/remodeling and clinical endpoint effects of bucindolol in beta-1 389 Arg/Gly genotypes. J Card Fail 2008, 14(6 Suppl 1):S40.
27. Lindenfeld J.L., Liggett S.B., Plehn J.F., et al. Ischemic cardiomyopathy response to bucindolol may be differentially influenced by beta-1 389 Arg/Gly and alpha-2c genotypes. J Card Fail 2008, 14(6 Suppl 1):S77.
28. Mason D.A., Moore J.D., Green S.A., et al. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 1999, 274:12670-12674.
29. Mialet Perez J., Rathz D.A., Petrashevskaya N.N., et al. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 2003, 9:1300-1305.
30. Sehnert A.J., Daniels S.E., Elashoff M., et al. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol 2008, 52:644-651.
31. White H., deBoer R.A., Maqbool A., et al. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail 2003, 5:463-468.
32. Domanski M., Kraus-Steinrauf H., Massie M., et al. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail 2003, 9(5):354-363.
33. Walsh R., Farmer R., Kelly M., et al. Human myocardial b1 389 Arg/Arg adrenergic receptors exhibit a propensity for constitutively active, high affinity agonist binding and are selectively inactivated by bucindolol [abstract]. J Card Fail 2008, 14(6):S8.
34. Bristow M.B., Krause-Steinrauf H., Nuzzo R., et al. Effect of baseline or changes in adrenergic activity on clinical outcomes in the b-blocker evaluation of survival trial. Circulation 2004, 110:1437-1442.
35. Magnusson Y., Levin M., Eggertsen R., et al. Ser49Gly of β1-adrenergic receptor is associated with effective β-blocker dose in dilated cardiomyopathy. Clin Pharmacol Ther 2005, 78:221-231.
36. Forleo C., Sorrentino S., Guida P., et al. β1- and β2-adrenergic receptor polymorphisms affect susceptibility to idiopathic dilated cardiomyopathy. J Cardiovasc Med (Hagerstown) 2007, 8(8):589-595.
37. Shin J., Lobmeyer M., Gong Y., et al. Relation of β2-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. Am J Cardiol 2007, 99(2):250-255.
38. McNamara D.M., Tam S.W., Sabolinski M.L., et al. Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure. J Am Coll Cardiol 2006, 48:1277-1282.
39. de Denus S., Zakrzewski-Jakubiak M., Dube M.P., et al. Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan. Ann Pharmacother 2008, 42:925-932.
40. Kurland L., Melhus H., Karlsson J., et al. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens 2002, 20:657-663.
41. Cicoira M., Rossi A., Bonapace S., et al. Effects of ACE gene insertion/deletion polymorphism on response to spironolactone in patients with chronic heart failure. Am J Med 2004, 116:657-661.
42. Agerholm-Larsen B., Nordestgaard B., Tybjaerg-Hansen A. ACE gene polymorphism in cardiovascular disease: meta analysis of small and large studies. Arterioscler Thromb Vasc Biol 2000, 20:484-492.
43. McNamara D.M., Holubkov R., Janosko K., et al. Pharmacogenetic interactions between beta blocker therapy and the angiotensin converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 2001, 103:1644-1648.
44. McNamara D.M., Holubkov R., Postava L., et al. Pharmacogenetic interactions between ACE inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol 2004, 44:2019-2026.
45. de Groote P., Helbecque N., Lamblin N. Beta-adrenergic receptor blockade and the angiotensin-converting enzyme deletion polymorphism in patients with chronic heart failure. Eur J Heart Fail 2004, 6(1):17-21.
46. Schieffer B. ACE gene polymorphism and coronary artery disease: a question of persuasion or statistical confusion?. Arterioscler Thromb Vasc Biol 2000, 20:281.
47. Belardinelli R., Georgiou D., Cianci G., et al. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. Circulation 1999, 99(9):1173-1182.
48. Whellan D.J., O'Connor C.M., Lee K.L., et al. HF-ACTION Trial Investigators. Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): design and rationale. Am Heart J 2007, 153(2):201-211.
49. Eisenach J.H., Barnes S.A., Pike T.L., et al. Arg16/Gly β2-adrenergic receptor polymorphism alters the cardiac output response to isometric exercise. J Appl Physiol 2005, 99:1776-1781.
50. Trombetta I., Batalha L., Rondon M., et al. Gly16 + Glu27 β2-adrenoceptor polymorphisms cause increased forearm blood flow responses to mental stress and handgrip in humans. J Appl Physiol 2005, 98:787-794.
51. McCole S., Shuldiner A., Brown M., et al. β2- and β3-Adrenergic receptor polymorphisms and exercise hemodynamics in postmenopausal women. J Appl Physiol 2004, 96:526-530.
52. Wagoner L., Craft L., Singh B., et al. Polymorphisms of the β2-adrenergic receptor determine exercise capacity in patients with heart failure. Circ Res 2000, 86:834-840.
53. Kritchevsky S., Nicklas B., Visser M., et al. Angiotensin-converting enzyme insertion/deletion genotype, exercise, and physical decline. JAMA 2005, 294(6):691-698.
54. Abraham M., Olson L., Joyner M., et al. Angiotensin-converting enzyme genotype modulates pulmonary function and exercise capacity in treated patients with congestive stable heart failure. Circulation 2002, 106:1794-1799.
55. Wieneke H., Naber C., Piaszek L., et al. Better identification of patients who benefit from implantable cardioverter defibrillators by genotyping the G protein β3 subunit (GNB3) C825T polymorphism. Basic Res Cardiol 2006, 101(5):447-451.
56. Chemello D., Rohde L., Pimentel M. Role of genetic polymorphisms to predict appropriate therapies in patients with implantable cardioverter defibrillators. J Card Fail 2008, 14(6 Suppl 1):S62.
57. Rogers J., Robinson S., Khanna A., et al. Transforming growth factor-ß polymorphisms and prediction of clinical outcome with prophylactic defibrillator implantation in chronic heart failure. Circulation 2007, 116(Suppl 2):S635.